Dissecting the genetic susceptibility for cholangiocarcinoma in primary sclerosing cholangitis

Hepatology

Volumn 47, Issue 1, 2008, Pages 8-10

  Lazaridis, Konstantinos N ^a,b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; PATHOGENESIS; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RECEPTORS, IMMUNOLOGIC;

EID: 38649086066     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22100     Document Type: Editorial

References (16)

1. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. Semin Liver Dis 2006;26:42-51.
2. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523-526.
3. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002;36:321-327.
4. Bergquist A, Glaumann H, Persson B, Broome U. Risk factors and clinical presentation of hepatobiliary carcinoma in patients with primary sclerosing cholangitis: a case-control study. HEPATOLOGY 1998;27:311-316.
5. Boberg KM, Bergquist A, Mitchell S, Pares A, Rosina F, Broome U, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol 2002;37:1205-1211.
6. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. HEPATOLOGY 2000;31:7-11.
7. Malhi H, Gores GJ. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J Hepatol 2006;45:856-867.
8. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. HEPATOLOGY 1995;22:1404-1408.
9. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005;50:1734-1740.
10. Baron TH, Harewood GC, Rumalla A, Pochron NL, Stadheim LM, Gores GJ, et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004;2:214-219.
11. Moreno Luna LE, Kipp B, Halling KC, Sebo TJ, Kremers WK, Roberts LR, et al. Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006;131:1064-1072.
12. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007;7:737-744.
13. Melum E, Karlsen T, Schrumpf E, Bergquist A, Thorbsy E, Boberg K, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. HEPATOLOGY 2007;47. DOI: hep.21964.
14. Mistry AR, O'Callaghan CA. Regulation of ligands for the activating receptor NKG2D. Immunology 2007;121:439-447.
15. Juran BD, Lazaridis KN. Genomics and complex liver disease: challenges and opportunities. HEPATOLOGY 2006;44:1380-1390.
16. Lazaridis KN, Juran BD. American Gastroenterological Association Future Trends Committee report: the application of genomic and proteomic technologies to digestive disease diagnosis and treatment and their likely impact on gastroenterology clinical practice. Gastroenterology 2005;129:1720-1752.